Analysis of bioMARKer distribution and individual reproducibility under rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation (R-MARK Study, CVI ARO2) - Hirota, N; Suzuki, S; Yamasaki, M (Int Heart J, 2020)